Sionna Therapeutics (SION) news
Recent news
Wedbush cuts Sionna Therapeutics to neutral from outperform; cuts target price to $5 from $53
Wedbush Securities has revised its stance on Sionna Therapeutics (NASDAQ:SION), downgrading the stock from Outperform to Neutral and significantly lowering its price target to $5 from $53. The adjustment follows evolving expectations regarding the company’s clinical development timeline and data…
AInvest Wire · Aug 11, 2026RBC raises Sionna Therapeutics to sector perform from underperform; cuts target price to $5 from $23
AInvest Wire · Aug 10, 2026Sionna Therapeutics shares down 91% after co's experimental drug misses mid-stage trial goal
AInvest Wire · Aug 10, 2026Sionna Therapeutics shares sink 87% after topline data update
AInvest Wire · Aug 10, 2026Sionna: plans actions to preserve capital, mulling next steps
Sionna Therapeutics, Inc. (Nasdaq: SION), a clinical-stage biopharmaceutical company focused on developing novel treatments for cystic fibrosis (CF), continues to advance its pipeline while maintaining a strong financial position. As of June 30, 2026, the company reported $268.3 million in cash and…
AInvest Wire · Aug 10, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.